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Background. Online platforms offer opportunities for support in changing lifestyle and taking responsibility for one’s health, but
engaging patients with type 2 diabetes is challenging. Previous studies have shown that patients interested in platforms were more
often male, younger, and higher educated. This study aims to investigate differences in clinical and psychological characteristics
between users and nonusers of a newly developed platform. Methods. A prospective study started in the Drenthe region of
Netherlands. Participants in the study concerning quality of care and quality of life were additionally invited to use the platform.
Results. 633 patientswere registered after they opted for platformuse.Of these patients, 361 (57.0%) never logged on, 184 (29.1%)were
labeled “curious” users, and 88 (13.9%) were identified as “active” users. Users had lower HbA1c levels andmore often hypertension
compared to nonusers, and reported higher quality of life, better well-being, lower diabetes-related distress, and better medication
adherence.Discussion. Platformuse was associated withmore favorable clinical and psychological characteristics relative to nonuse.
Those with greater severity of disease, lower mood, and progression of disease used the platform the least. Other approaches need
to be developed to reach these patients. Furthermore, improving the platform could also help to reach them.This trial is registered
with Clinicaltrials.gov NCT01570140.
1. Background
Type 2 diabetes mellitus (T2DM) in itself is associated with
poorer health-related quality of life (HRQoL) [1]. People with
T2DM are susceptible to develop long term complications,
such as retinopathy, neuropathy, nephropathy, and chronic
heart disease, which negatively influence HRQoL [2]. To pre-
vent or delay development of these long term complications,
adequate treatment modalities are necessary which mainly
involve lifestyle changes and pharmacological treatment.
Adherence to medication prescription and implementing life
style changes are often better maintained and facilitated,
when patients consider themselves more responsible for
their treatment and have more knowledge regarding the
causes and consequences of their disease. Improvements in
knowledge about their disease can be described as promotion
of health literacy. e-Health applications, such as web-portals,
teleconsultation, and online care platforms, have the potential
to support patients in changing lifestyle and taking more
responsibility for their own health [3]. However, varying
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were not registered for
platform use by GP or PN
633 patients (41.8%)
were registered for
platform use by GP or PN
361 patients (57.0%) did
not log on to the
platform (nonusers)
272 patients (43.0%)
logged on to the
platform (users)
184 patients (29.1%)
logged on to the
platform once or twice
(curious users)
88 patients (13.9%)
logged on to the
sessions with a minimum
platform for at least two 
duration of 5 minutes
per session (active users) 
Figure 1: Flowchart of patients and definitions.
effects on clinical outcomes, quality of life, degree of self-care,
perceived stress levels, patient satisfaction, and costs have
been reported [4–10].
Previous studies showed that patientswhowere interested
in using an online care platform were more often male,
younger, and higher educated [11, 12]. However, within the
subgroup of interested patients these differences were not
found between actual users and nonusers [11]. In addition,
other factors associated with higher portal enrollment and
utilization are higher income, nonblack race, higher self-
efficacy, and having better regulated diabetes [13]. Identifying
the differences between platform users and nonusers could
provide information to help target and support nonusers in
becoming more active in their diabetes self-management.
The aim of the present, explorative study was to inves-
tigate possible differences in demographic, clinical, and
psychological characteristics between users and nonusers of
the platform e-Vita.
2. Methods
2.1. Study Design. We performed a cross-sectional analysis
of baseline data of users and nonusers of the online patient
platform e-Vita. Data was obtained from a prospective
observational cohort study. Detailed information about the
methods and design of the study as a whole can be found
elsewhere [14].
2.2. Study Population and Setting. Forty-three out of 110
general practices in the Drenthe region of the Netherlands
invited their T2DMpatients for participation in a prospective
observational cohort study concerning quality of care and
HRQoL. Patients were also invited to use the online care
platform e-Vita, in addition to their usual treatment. Patients
interested in using the platform were registered by their
practice nurse (PN) and received a user ID. In this ongoing
study, participants were recruited from May 2012 onward.
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Subscale general practice 0.966






Subscale general diet 0.875
Subscale specific diet 01
Subscale total diet 0.4462
Subscale exercise 0.663
Subscale blood-glucose testing 0.912
Subscale foot-care 0.593
1Because of the negative intercorrelation between the two items Cronbach’s alpha is reported to be 0.
2The alpha for the subscale total diet is lower than that for the subscale general diet due to the low reliability of the subscale specific diet.
The current analysis includes patients recruited from May
2012 till March 2014.
2.3. Measurements. Demographic and clinical data were
obtained from the personal health record systems of the
general practitioners (GP), based on a core dataset of T2DM
related information as advised by the Dutch Diabetes Fed-
eration and the Dutch College of General Practitioners [14].
All T2DM patients participating in the study filled in a range
of validated questionnaires concerning perceived quality of
life measured by the EuroQol Five Dimension (EQ-5D)
Scale [15–17], emotional well-being measured by the World
HealthOrganizationWellbeing Index 5-Item (WHO-5) ques-
tionnaire [18, 19], diabetes-related distress measured by the
Problem Areas in Diabetes 5-Item (PAID-5) questionnaire
[20], diabetes self-care behavior measured by 7 Dimensions
of the Summary of Diabetes Self-Care Activities (SDSCA)
questionnaire [21], and quality of received care measured
by the Europep [22]. Suboptimal emotional well-being was
defined by a raw score lower than 13 on the WHO-5 [23].
Additional questions about smoking habits, employment,
and educational background were also included. To identify
users and nonusers, registration data from the application
software and log-files were used.
2.4. Description of e-Vita Platform. The e-Vita platform for
T2DM patients (accessible through the login button on
https://www.e-vita.nl/) [11, 14, 24] contains the following
components: (1) an overview of health data concerning
annual check-ups from 2009 onward, (2) educational mod-
ules meant to support care through self-management by
setting person-specific goals and actions [25], (3) prompting
patient self-monitoring of clinical values, (4) educational
modules aimed at increasing diabetes knowledge, and (5)
providing reliable information on T2DM in general.
2.5. Users and Nonusers. Information about login status and
log-data were used to group patients into nonusers and users.
All patients who logged in at least once were considered as
users. Patients who had been online for at least two sessions
with a minimum of five minutes per session were defined as
“active” users; other patients were defined as “curious” users.
A session included all logins to the platform within thirty
minutes [24].
2.6. Statistical Analyses. Statistical analyses were performed
using SPSS version 20 (IBMCorporation, Somers, NY, USA).
Quantitative variables are described in means and standard
deviations when normally distributed; otherwise medians
and interquartile ranges are also described. Categorical vari-
ables are described in numbers and percentages. To identify
differences in the domains of interest between the different
groups of users, the Linear Mixed Models procedure was
used, with groups of users being fixed factors (nonusers
being the reference group), while adjusting for age and sex.
Fisher’s exact test was used for categorical data. Differences
were considered to be significant at a 𝑝 value of <0.05. In
addition, results are adjusted for age and gender. Because
of the explorative design of this study, no corrections for
multiple testing were made [26]. Instead, the calculated 𝑝
values are only used as an indication of to what extent a
difference could be interesting for further research.
2.7. Ethics. This study was approved by the Medical Ethical
Review Committee of Isala, Zwolle, the Netherlands, and
registered in Clinicaltrials.gov under number NCT01570140.
3. Results
In the period fromMay 2012 toMarch 2014, 3191 patients were
invited to participate in the cohort study and to use the e-Vita
Journal of Diabetes Research 5
Table 3: Results of multivariate analysis, adjusted for age and gender.
𝑏-coefficient 95% CI 𝑝 valueLower bound Upper bound
T2DM duration in years
Intercept 0.018 −2.325 2.360 0.988
Platform use 0.186
Active users −0.845 −1.876 0.186 0.108
Curious users −0.511 −1.300 0.277 0.203
Nonusers Ref. Cat.
Male −0.121 −0.832 0.589 0.738
Female Ref. Cat.
Age 0.101 0.064 0.138 <0.0005
HbA1c in mmol/mol
Intercept 53.431 48.931 57.931 <0.0005
Platform use <0.0005
Active users −3.624 −5.627 −1.621 <0.0005
Curious users −1.989 −3.516 −0.462 0.011
Nonusers Ref. Cat.
Male 1.103 −0.270 2.477 0.115
Female Ref. Cat.
Age −0.055 −0.127 0.016 0.126
BMI
Intercept 37.430 34.658 40.202 <0.0005
Platform use 0.924
Active users 0.079 −1.159 1.317 0.900
Curious users 0.189 −0.747 1.124 0.692
Nonusers Ref. Cat.
Male −1.087 −1.931 −0.244 0.012
Female Ref. Cat.
Age −0.113 −0.156 −0.069 <0.0005
EQ-5D
Intercept 0.866 0.773 0.958 <0.0005
Platform use 0.022
Active users 0.008 −0.031 0.047 0.674
Curious users 0.044 0.013 0.076 0.006
Nonusers Ref. Cat.
Male 0.056 0.027 0.085 <0.0005
Female Ref. Cat.
Age −0.001 −0.002 0.001 0.343
EQ-VAS
Intercept 71.007 61.663 80.350 <0.0005
Platform use 0.019
Active users 2.291 −1.691 6.275 0.259
Curious users 4.611 1.384 7.838 0.005
Nonusers Ref. Cat.
Male 2.977 0.095 5.859 0.043
Female Ref. Cat.
Age 0.030 −0.118 0.178 0.690
WHO-5
Intercept 58.138 48.911 67.365 <0.0005
Platform use 0.065
Active users −0.089 −4.008 3.829 0.964
Curious users 3.609 0.446 6.773 0.025
Nonusers Ref. Cat.
Male 5.766 2.932 8.600 <0.0005
Female Ref. Cat.
Age 0.142 −0.004 0.289 0.057
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Table 3: Continued.
𝑏-coefficient 95% CI 𝑝 valueLower bound Upper bound
PAID-5
Intercept 5.129 3.520 6.737 <0.0005
Platform use 0.004
Active users −0.511 −1.195 0.173 0.143
Curious users −0.929 −1.480 −0.378 0.001
Nonusers Ref. Cat.
Male −0.143 −0.639 0.353 0.571
Female Ref. Cat.
Age −0.037 −0.062 −0.011 0.005
SDSCA-medication
Intercept 6.087 5.575 6.600 <0.0005
Platform use 0.028
Active users 0.081 −0.132 0.296 0.458
Curious users 0.236 0.063 0.408 0.008
Nonusers Ref. Cat.
Male 0.096 −0.058 0.250 0.222
Female Ref. Cat.
Age 0.010 0.002 0.018 0.020
platform. 633 patients were registered for care platform use.
See Figure 1 for the patient flow.
Table 1 shows all differences and other notable character-
istics for the comparison between nonusers, curious users,
and active users of the platform. No differences were found
in demographical characteristics between nonusers, curious
users, and active users. HbA1c level of nonusers was higher
compared to curious users (𝑝 = 0.038) and to active users
(𝑝 = 0.001). Curious and active users were more often
knownwith hypertension compared to nonusers (𝑝 = 0.025).
Curious users assessed the GP better on one question of the
Europep compared to nonusers and active users (𝑝 = 0.047).
Curious users scored higher on EQ-5D (𝑝 = 0.030) and EQ-
VAS (0.032) compared to nonusers, with no significant differ-
ences between curious users and active users or nonusers and
active users. In addition, curious users’ WHO-5 score as well
as their answers to the individualWHO-5 questions reported
less depressive symptoms compared to nonusers and active
users. Curious users scored lower on PAID-5 compared to
nonusers (𝑝 = 0.016), with no significant differences between
curious users versus active users and nonusers versus active
users. Curious users performed better on one dimension of
self-reported self-management activities (medication intake)
compared to nonusers (𝑝 = 0.020), with no significant
difference between curious users versus active users and
nonusers versus active users. Table 2 shows the Cronbach’s
alpha for all the multi-item scales.
See Appendix A for tables with all characteristics as men-
tioned in the methods section for the comparison between
nonusers and users. See Appendix B for tables with all
characteristics for the comparison between nonusers, curious
users, and active users.
The differences in characteristics between nonusers, curi-
ous users, and active users have also been adjusted for
age and gender in a multivariate analysis. The results are
shown in Table 3. 𝑝 values below 0.05 were found for differ-
ences regarding HbA1c between active users and nonusers
(−3.624mmol/mol) as well as between curious users and
nonusers (−1.989mmol/mol) and for differences between
curious users and nonusers regarding EQ-5D (0.044), EQ-
VAS (4.611), WHO-5 (3.609), PAID-5 (−0.929), and medica-
tion intake (0.236).
4. Discussion
In this exploratory study we found that only a small amount
of clinical and psychological characteristics were associated
with platform use. Curious users as well as active users had
lower HbA1c compared to nonusers, which is in agreement
with other studies [27, 28]. The more frequent presence of
hypertension in curious and active users, however, contra-
dicts with these studies. Curious users scored higher on EQ-
5D and EQ-VAS and lower on PAID-5. Curious users scored
also better on medication intake, which may reflect higher
self-efficacy, in agreement with the study by Sarkar et al.
[29]. After adjustment for age and gender, the difference in
WHO-5 score between curious users and nonusers was also
significant.
We observed that most of the patients, who were reg-
istered for platform use, never logged on. This could be
Journal of Diabetes Research 7
Table 4: Demographic and clinical characteristics of users and nonusers.
Demographic and clinical
parameters
𝑛 (%)/mean ± SD/median (25–75
quartiles)
Nonusers
(𝑛 = 361) Missing Users (𝑛 = 272) Missing
Univariate
𝑝 value
Men 214 (59.3) 0 (0) 163 (59.9) 0 (0) 0.95
Age in years 62.1 ± 9.563.0 (56.5–68.0) 0 (0)
61.8 ± 9.4
62.5 (57.0–68.0) 0 (0) 0.732
Ethnicity
Caucasian 292 (99.0) 66 (18.3) 208 (100) 64 (2.5) 0.271
Other 3 (1.0) 0 (0)
T2DM duration in years 6.2 ± 4.66.0 (2.0–9.0) 9 (2.5)
5.6 ± 4.4
5.0 (2.0–8.0) 1 (0.4) 0.068
HbA1c in mmol/mol 50.6 ± 9.550.0 (45.0–54.0) 3 (0.8)
48.2 ± 7.3
47.0 (43.0–53.0) 0 (0) <0.0005
BMI 29.8 ± 4.929.0 (26.5–32.5) 3 (0.8)
30.0 ± 6.0
28.7 (26.3–32.4) 2 (0.7) 0.724
Systolic blood pressure in mmHG 135.6 ± 15.5 0 (0) 136.5 ± 16.0 4 (1.5) 0.463
Cholesterol in mmol/L 4.4 ± 1.0 4 (1.1) 4.4 ± 0.9 2 (0.7) 0.499
HDL in mmol/L 1.3 ± 0.4 4 (1.1) 1.3 ± 0.4 3 (1.1) 0.581
Cholesterol/HDL ratio 3.6 ± 1.1 160 (44.3) 3.6 ± 1.3 92 (33.8) 0.899
LDL in mmol/L 2.4 ± 0.9 12 (3.3) 2.3 ± 0.8 6 (2.2) 0.240
Triglycerides in mmol/L 1.7 ± 1.01.5 (1.0–2.1) 7 (1.9)
1.8 ± 1.2
1.5 (1.1–2.1) 2 (0.7) 0.482
Creatinine in 𝜇mol/L 78.6 ± 17.277.0 (67.0–88.0) 6 (1.7)
79.9 ± 17.5
79.0 (67.0–90.0) 1 (0.4) 0.359
Alb./creat. ratio in mg/mmol
Men 2.0 ± 4.40.7 (0.3–1.5) 23 (10.7)
1.9 ± 5.8
0.5 (0.3–1.5) 25 (15.3) 0.853
Women 1.6 ± 3.50.7 (0.3–1.5) 31 (21.1)
0.9 ± 1.1
0.6 (0.4–1.2) 18 (16.5) 0.070
MDRD in mL/min/1.73m2 79.1 ± 49.075.0 (61.0–88.0) 5 (1.4)
76.0 ± 16.6
74.0 (61.0–87.0) 1 (0.4) 0.329
Smoking
Yes 54 (15.1) 3 (0.8) 41 (15.1) 1 (0.4) 0.306
Before 158 (44.1) 104 (38.4)
No 146 (40.8) 126 (46.5)
Alcohol consumption in units/day
0 166 (58.9) 79 (21.9) 139 (60.7) 43 (15.8) 0.870
1 61 (21.6) 52 (22.7)
2 39 (13.8) 30 (13.1)
3 11 (3.9) 7 (3.1)
4 4 (1.4) 1 (0.4)
5 0 (0) 0 (0)
6 1 (0.4) 0 (0)
Employment
Fulltime/part-time working 99 (34.3) 72 (19.9) 81 (34.0) 34 (12.5) 0.909
Retired 134 (46.4) 116 (48.7)
Unemployed/ housekeeper 38 (13.1) 29 (12.2)
Incapacitated 18 (6.2) 12 (5.0)
Educational level
None 0 (0) 73 (20.2) 1 (0.4) 35 (12.9) 0.017
Primary school 24 (8.3) 13 (5.5)
Low 127 (44.1) 79 (33.3)
Intermediate 86 (29.9) 81 (29.8)
High 51 (17.7) 63 (23.2)
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(𝑛 = 361) Missing
Users




Oral treatment only 251 (71.3) 9 (2.5) 192 (71.9) 5 (1.8) 0.702
Insulin treatment only 4 (1.1) 9 (2.5) 1 (0.4) 5 (1.8) 0.931
Mix of oral and insulin treatment 40 (11.4) 9 (2.5) 23 (8.6) 5 (1.8) 0.248
No medication 57 (16.2) 9 (2.5) 51 (19.1) 5 (1.8) 0.417
Comorbidity or complication related
Calcium channel blockers 50 (14.2) 9 (2.5) 47 (17.6) 5 (1.8) 0.236
Beta blockers 128 (36.4) 9 (2.5) 110 (41.2) 5 (1.8) 0.145
Diuretics 121 (34.4) 9 (2.5) 94 (35.2) 5 (1.8) 0.870
Ace and RAAS inhibitors 196 (55.7) 9 (2.5) 141 (52.8) 5 (1.8) 0.480
Other blood pressure lowering
medications 3 (0.9) 9 (2.5) 1 (0.4) 5 (1.8)
0.637
Lipid lowering medication 280 (79.5) 9 (2.5) 213 (79.8) 5 (1.8) 0.847
Table 6: Complications and risk factors of users and nonusers.
Complications and risk factors
𝑛 (%)
Nonusers
(𝑛 = 361) Missing
Users
(𝑛 = 272) Missing
Univariate
𝑝 value
Cardiovascular, total 225 (96.2) 127 (35.2) 187 (98.4) 82 (30.1) 0.240
Cardiovascular, specific
Angina pectoris 41 (21.7) 172 (47.6) 28 (19.7) 130 (47.8) 0.787
Myocardial infarct 29 (15.3) 172 (47.6) 23 (16.0) 128 (47.1) 0.880
Other/chronic ischemic heart diseases 34 (16.1) 150 (41.6) 24 (13.6) 96 (35.3) 0.569
Hypertension 191 (84.1) 134 (37.1) 164 (93.2) 96 (35.3) 0.008
TIA 12 (6.4) 174 (48.2) 7 (5.0) 133 (48.9) 0.642
CVA 13 (7.0) 176 (48.8) 10 (7.1) 132 (48.5) 1.000
Intermittent claudication 7 (3.3) 150 (41.6) 7 (4.0) 96 (35.3) 0.788
Aortic aneurysms 4 (1.9) 150 (41.6) 2 (1.1) 96 (35.3) 0.693
CABG 15 (5.1) 68 (18.8) 11 (5.4) 68 (25.0) 1.000
PTCA 28 (9.6) 68 (18.8) 14 (6.8) 67 (24.6) 0.327
Heart failure 14 (8.1) 189 (52.4) 10 (7.4) 136 (50.0) 0.834
Retinopathy 19 (9.3) 156 (43.2) 18 (10.2) 95 (34.9) 0.863
Renal impairment 35 (18.6) 173 (47.9) 26 (18.6) 132 (48.5) 1.000
Albuminuria
Men 30 (14.5) 7 (3.3) 20 (12.6) 4 (2.5) 0.647
Women 8 (5.8) 8 (5.4) 1 (1.0) 5 (4.6) 0.082
Neuropathy 49 (22.2) 140 (38.8) 39 (22.4) 98 (36.0) 1.000
Foot complication
SIMMs 0 228 (77.6) 67 (18.6) 161 (76.7) 62 (22.8) 0.783
SIMMs 1 57 (19.4) 40 (19.0)
SIMMs 2 or 3 9 (3.1) 9 (4.3)
Psychiatric disorders 19 (9.0) 150 (41.6) 9 (5.1) 96 (35.3) 0.124
SIMMS refers to risk factors in the diabetic foot, the number is the stage which ranges from 0–3.
0: no loss of protective sensibility (PS) & Peripheral arterial disease (PAV).
1: loss of PS or PAV, with no signs of increased local pressure.
2: loss of PS in combination with and/or PAV and/or signs of local elevated pressure.
3: ulcer or amputation in history.
Journal of Diabetes Research 9
Table 7: Scores on quality of care (Europep) of users and nonusers.




(𝑛 = 361) Missing
Users
(𝑛 = 272) Missing
Univariate
𝑝 value
What is your assessment of the general practitioner over
the last 12 months with respect to the following?
Making you feel you have time during consultation 337 (97.4) 15 (4.2) 256 (98.1) 11 (4.0) 0.622
Showing interest in your personal situation 324 (94.5) 18 (5.0) 246 (94.6) 12 (4.4) 0.864
Making it easy for you to tell him or her about your
problem 323 (93.4) 15 (4.2) 245 (96.5) 18 (6.6)
0.110
Involving you in decisions about your medical care 311 (92.3) 24 (6.6) 239 (94.1) 18 (6.6) 0.290
Listening to you 322 (92.3) 12 (3.3) 243 (94.6) 15 (5.5) 0.270
Keeping your records and data confidential 310 (95.7) 37 (10.2) 236 (95.9) 26 (9.6) 0.846
Providing quick relief of your symptoms 272 (87.5) 50 (13.9) 201 (85.9) 38 (14.0) 0.635
Helping you to feel well so that you can perform your
normal daily activities 265 (89.8) 66 (18.3) 196 (91.2) 57 (21.0)
0.483
Thoroughness of the approach to your problems 308 (91.4) 24 (6.6) 227 (89.7) 19 (7.0) 0.786
Your physical examination 292 (90.1) 37 (10.2) 222 (92.1) 31 (11.4) 0.327
Offering services for preventing diseases (screening,
health checks, and immunizations) 286 (91.4) 48 (13.3) 225 (92.6) 29 (10.7)
0.655
Explaining the purpose of examinations, tests, and
treatments 307 (93.0) 31 (8.6) 240 (93.8) 16 (5.9)
0.518
Telling you enough about your symptoms and/or illness 306 (92.2) 29 (8.0) 238 (93.3) 17 (6.3) 0.448
Helping you deal with emotions related to your health
status 198 (86.8) 133 (36.8) 133 (84.7) 115 (42.3)
0.888
Helping understand why it is important to follow the
GP’s advice 295 (89.7) 32 (8.9) 219 (89.4) 27 (9.9)
0.894
Knowing what has been done or told during previous
contacts in the practice 270 (84.9) 43 (11.9) 219 (89.4) 27 (9.9)
0.071
Preparing you for what to expect from specialists,
hospital care, and other care providers 199 (85.4) 128 (35.5) 156 (83.5) 85 (31.3) 0.513
What is your assessment of the general practice over the
last 12 months with respect to the following?
The helpfulness of the practice staff (other than the
doctor) to you 313 (93.4) 26 (7.2) 235 (92.9) 19 (7.0)
0.878
Getting an appointment to suit you 301 (88.5) 21 (5.8) 224 (86.5) 13 (4.8) 0.639
Getting through to the practice on telephone 249 (73.0) 20 (5.5) 180 (69.5) 13 (4.8) 0.662
Being able to talk to the general practitioner on the
telephone 167 (70.5) 124 (34.3) 106 (63.1) 104 (38.2)
0.150
Waiting time in the waiting room 246 (71.3) 16 (4.4) 170 (65.4) 12 (4.4) 0.175
Providing quick services for urgent health problems 241 (90.3) 94 (26.0) 171 (86.8) 75 (27.6) 0.398
influenced by (an insufficient) intrinsic motivation and (no)
intention to change behaviours. Another explanation could
be that patients do not see the platform as useful or as
an added value to regular treatment. As an alternative
explanation, login procedures might be too difficult and after
trying for some time they might give up.
Previous research showed that web-portals and online
care platforms are susceptible to implementation problems,
low participation rates, and nonadherence, which, amongst
others, can be caused by a mismatch in expectations between
software developers, health care providers, and users [30–
37]. Other reasons for limited use of care platforms or
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Table 8: Scores on quality of life (EQ-5D), well-being (WHO-5), diabetes-related distress (PAID-5), and self-care behavior (SDSCA).
EQ-5D, WHO-5, PAID-5, and SDSCA
𝑛 (%)/mean ± SD/median (25–75 quartiles)
Nonusers
(𝑛 = 361) Missing
Users
(𝑛 = 272) Missing
Univariate
𝑝 value
EQ-5D index-score 0.9 ± 0.2 72 (19.9) 0.9 ± 0.1 36 (13.2) 0.028
EQ-VAS 74.7 ± 17.480.0 (60.0–90.0) 74 (20.5)
78.4 ± 14.9
80.0 (71.0–90.0) 40 (14.7)
0.014
WHO-5 index-score 70.4 ± 17.976.0 (60.0–80.0) 76 (21.1)
72.7 ± 14.2
76.0 (68.0–80.0) 38 (14.0)
0.096
WHO-5 score indicates suboptimal well-being,
screening depression advised 36 (12.6) 76 (21.1) 17 (7.3) 38 (14.0)
0.018
WHO-5 answers advise screening depression 43 (15.5) 76 (21.1) 17 (7.3) 38 (14.0) 0.004
PAID-5 total score 2.8 ± 3.12.0 (0.0–4.5) 76 (21.1)
2.0 ± 2.5
1.0 (0.0–3.0) 38 (14.0)
0.005
PAID-5 score indicates distress 15 (5.3) 76 (21.1) 6 (2.6) 38 (14.0) 0.058
SDSCA
General diet in number of days 5.4 ± 1.86.0 (5.0–7.0) 76 (21.1)
5.6 ± 1.8
6.0 (5.0–7.0) 37 (13.6)
0.269
Specific diet in number of days 5.6 ± 1.15.7 (4.7–6.3) 73 (20.2)
5.7 ± 1.0
6.0 (5.3–6.7) 34 (12.5)
0.056
Exercise in number of days 4.0 ± 2.04.0 (2.5–5.5) 72 (19.9)
4.0 ± 1.8
4.0 (2.5–5.5) 34 (12.5)
0.919
Blood-glucose in number of days 2.1 ± 2.21.0 (0.0–4.0) 74 (20.5)
2.0 ± 2.2
1.0 (0.5–3.5) 34 (12.5)
0.675
Foot-care in number of days 1.9 ± 2.01.5 (0.0–3.5) 72 (19.9)
1.9 ± 2.0
1.0 (0.0–3.5) 34 (12.5)
0.695
Medication in number of days 6.7 ± 1.07.0 (7.0–7.0) 73 (20.2)
6.9 ± 0.5
7.0 (7.0–7.0) 34 (12.5)
0.013
Smoking 54 (25.1) 146 (40.4) 38 (22.8) 105 (38.6) 0.418
nonadherence rates are as follows: abundance of function-
alities on a platform, no connection with the needs of
patients, implementation bymanagement only without active
involvement of care providers, no embedding in the regular
care process, no space for habituation, underestimation of the
complexity of lifestyle changes in general [38], and barriers to
easy access to a portal (e.g., complicated login procedures).
Despite the use of focus groups for designing and testing,
these reasons might also be applicable to the e-Vita platform
and improvements could be made.
The current study has some limitations. A preselection
of participants could in part have influenced results. Only
patients who expressed their interest received a user-ID [14];
see also Figure 1. Relevant and significant differences might
be more difficult to find.
Data were not complete for all patients, especially with
regard to complications and risk factors (complete for 50–
60%; see Tables 6 and 11). This may have led to an under-
estimation of presence of complications and risk factors. In
addition, not all patients were seen by their GP or PN for the
regular yearly check-up in the year 2012, which contributed to
missing values in clinical parameters. Some questions about
the assessment of the general practice and the general prac-
titioner were poorly answered in general. A reason for this
could be social desirability; patients may not like to be nega-
tive about their GP and prefer not answering these questions.
Although the online care platform e-Vita was designed for
being suitable for all T2DM patients, a general assumption
is that those with greater severity of disease, lower mood,
progression of the disease, and complications would probably
benefit most from an online care platform. However, when
assessing the presented results, these patients use the platform
the least.
Possibly, the current users were already more in control
of their life and health and could therefore be more open to
other forms of support, including e-Health facilities. Chal-
lenges to reach other patients remain manifold. A patients’
passive attitude may not be overcome by only providing
e-facilities, since one’s interest and the sense of disease
burden are low or even absent in the majority of the T2DM
population. Factors as knowledge, motivation, and intention
could be considered in future research.
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Table 9: Demographic and clinical characteristics of curious users, active users, and nonusers.
Demographic and clinical
parameters
𝑛 (%)/mean ± SD/median
(25–75 quartiles)
Nonusers
(𝑛 = 361) Missing
Curious users
(𝑛 = 184) Missing
Active users
(𝑛 = 88) Missing
Univariate
𝑝 value









0 (0) 62.0 ± 9.463.0 (57.0–67.0) 0 (0) 0.935
Ethnicity
Caucasian 292 (99.0) 66 (18.3) 143 (100) 41 (22.3) 65 (100) 23 (6.1) 0.706
Other 3 (1.0) 0 (0) 0 (0) 0.382
T2DM duration in years 6.2 ± 4.66.0 (2.0–9.0) 9 (2.5)
5.7 ± 4.4
5.0 (2.0–8.0) 1 (0.5)
5.4 ± 4.4



























Systolic blood pressure in
mmHG 135.6 ± 15.5 0 (0) 137.2 ± 16.3 2 (1.1) 135.1 ± 15.3 2 (2.3) 0.463
Cholesterol in mmol/L 4.4 ± 1.0 4 (1.1) 4.4 ± 0.8 0 (0) 4.4 ± 0.9 2 (2.3) 0.775
HDL in mmol/L 1.3 ± 0.4 4 (1.1) 1.2 ± 0.3 1 (0.5) 1.3 ± 0.4 2 (2.3) 0.071
Cholesterol/HDL ratio 3.6 ± 1.1 160 (44.3) 3.7 ± 1.4 57 (31.0) 3.4 ± 1.0 35 (39.8) 0.185
LDL in mmol/L 2.4 ± 0.9 12 (3.3) 2.4 ± 0.8 3 (1.6) 2.3 ± 0.8 3 (3.4) 0.473
Triglycerides in mmol/L 1.7 ± 1.01.5 (1.0–2.1) 7 (1.9)
1.8 ± 1.3
1.5 (1.1–2.1) 0 (0)
1.7 ± 1.0














Alb./creat. ratio in mg/mmol
Men 2.0 ± 4.40.7 (0.3–1.5) 23 (10.7)
2.2 ± 6.9
0.5 (0.3–1.5) 18 (15.9)
1.3 ± 1.7
0.7 (0.3–1.5) 7 (14.0) 0.636
Women 1.6 ± 3.50.7 (0.3–1.5) 31 (21.1)
1.1 ± 1.3
0.7 (0.4–1.5) 8 (11.3)
0.6 ± 0.5











Yes 54 (15.1) 3 (0.8) 30 (16.4) 1 (0.5) 11 (12.5) 0 (0) 0.382
Before 158 (44.1) 73 (39.7) 31 (35.2)
No 146 (40.8) 80 (43.7) 46 (52.3)
Alcohol consumption in
units/day
0 166 (58.9) 79 (21.9) 98 (60.9) 23 (12.5) 41 (60.3) 20 (22.7) 0.646
1 61 (21.6) 8 (23.6) 14 (20.6)
2 39 (13.8) 17 (10.6) 13 (19.1)
3 11 (3.9) 7 (4.3) 0 (0)
4 4 (1.4) 1 (0.5) 0 (0)
5 0 (0) 0 (0) 0 (0)
6 1 (0.4) 0 (0) 0 (0)
Employment
Fulltime/part-time
working 99 (34.3) 72 (19.9) 61 (39.6) 30 (16.3) 20 (23.8) 4 (4.5) 0.063
Retired 134 (46.4) 70 (45.5) 46 (54.8)
Unemployed/housekeeper 38 (13.1) 20 (13.0) 9 (10.7)
Incapacitated 18 (6.2) 3 (1.9) 9 (10.7)
Educational level
None 0 (0) 73 (20.2) 1 (0.7) 31 (16.8) 0 (0) 4 (4.5) 0.125
Primary school 24 (8.3) 9 (5.9) 4 (4.8)
Low 127 (44.1) 52 (34.0) 27 (32.1)
Intermediate 86 (29.9) 51 (33.3) 30 (35.7)
High 51 (17.7) 40 (26.1) 23 (27.4)
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(𝑛 = 361) Missing
Curious users
(𝑛 = 184) Missing
Active users




Oral treatment only 251 (71.3) 9 (2.5) 128 (71.5) 5 (2.7) 64 (72.7) 0 (0) 1.000
Insulin treatment only 4 (1.1) 9 (2.5) 1 (0.5) 5 (2.7) 0 (0) 0 (0) 0.899
Mix of oral and insulin
treatment 40 (11.4) 9 (2.5) 18 (10.1) 5 (2.7) 5 (5.7) 0 (0) 0.242
No medication 57 (16.2) 9 (2.5) 32 (17.9) 5 (2.7) 19 (21.6) 0 (0) 0.521
Comorbidity or complication
related
Calcium channel blockers 50 (14.2) 9 (2.5) 31 (17.3) 5 (2.7) 16 (18.2) 0 (0) 0.415
Beta blockers 128 (36.4) 9 (2.5) 74 (41.3) 5 (2.7) 36 (40.9) 0 (0) 0.324
Diuretics 121 (34.4) 9 (2.5) 63 (35.2) 5 (2.7) 31 (35.2) 0 (0) 0.979
Ace and RAAS inhibitors 196 (55.7) 9 (2.5) 94 (52.5) 5 (2.7) 47 (53.4) 0 (0) 0.738
Other blood pressure lowering
medications 3 (0.9) 9 (2.5) 0 (0) 5 (2.7) 1 (1.1) 0 (0) 0.357
Lipid lowering medication 280 (79.5) 9 (2.5) 141 (78.8) 5 (2.7) 72 (81.8) 0 (0) 0.868





(𝑛 = 361) Missing
Curious users
(𝑛 = 184) Missing
Active users
(𝑛 = 88) Missing
Univariate
𝑝 value
Cardiovascular, total 225 (96.2) 127 (35.2) 128 (98.5) 54 (29.3) 59 (98.3) 28 (31.8) 0.506
Cardiovascular, specific
Angina pectoris 41 (21.7) 172 (47.6) 21 (21.4) 86 (46.7) 7 (15.9) 44 (50.0) 0.698
Myocardial infarct 29 (15.3) 172 (47.6) 15 (15.3) 86 (46.7) 8 (17.4) 42 (47.7) 0.932
Other/chronic ischemic
heart diseases 34 (16.1) 150 (41.6) 18 (14.9) 63 (34.2) 6 (10.9) 33 (37.5) 0.750
Hypertension 191 (84.1) 134 (37.1) 113 (93.4) 63 (34.2) 51 (92.7) 33 (37.5) 0.025
TIA 12 (6.4) 174 (48.2) 4 (4.2) 88 (47.8) 3 (7.0) 45 (51.1) 0.747
CVA 13 (7.0) 176 (48.8) 6 (6.1) 86 (46.7) 4 (9.5) 46 (52.3) 0.745
Intermittent claudication 7 (3.3) 150 (41.6) 4 (3.3) 63 (34.2) 3 (5.5) 33 (37.5) 0.689
Aortic aneurysms 4 (1.9) 150 (41.6) 1 (0.8) 63 (34.2) 1 (1.8) 33 (37.5) 0.731
CABG 15 (5.1) 68 (18.8) 7 (5.0) 43 (23.4) 4 (6.3) 25 (28.4) 0.916
PTCA 28 (9.6) 68 (18.8) 9 (6.4) 43 (23.4) 5 (7.8) 24 (27.3) 0.588
Heart failure 14 (8.1) 189 (52.4) 9 (9.4) 88 (47.8) 1 (2.5) 48 (54.5) 0.409
Retinopathy 19 (9.3) 156 (43.2) 14 (11.7) 64 (34.8) 4 (7.0) 31 (35.2) 0.640
Renal impairment 35 (18.6) 173 (47.9) 15 (15.5) 87 (47.3) 11 (25.6) 45 (51.1) 0.350
Albuminuria
Men 30 (14.5) 7 (3.3) 14 (12.6) 2 (1.8) 6 (12.5) 2 (4.0) 0.908
Women 8 (5.8) 8 (5.4) 1 (1.4) 1 (1.4) 0 (0) 4 (10.5) 0.226
Neuropathy 49 (22.2) 140 (38.8) 30 (24.6) 62 (33.7) 9 (17.3) 36 (40.9) 0.594
Foot complication
SIMMs 0 228 (77.6) 67 (18.6) 105 (73.4) 41 (22.3) 56 (83.6) 21 (23.9) 0.524
SIMMs 1 57 (19.4) 31 (21.7) 9 (13.4)
SIMMs 2 or 3 9 (3.1) 7 (4.9) 2 (3.0)
Psychiatric disorders 19 (9.0) 150 (41.6) 7 (5.8) 63 (34.2) 2 (3.6) 33 (37.5) 0.317
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Table 13: Scores on quality of life (EQ-5D), well-being (WHO-5), diabetes-related distress (PAID-5), and self-care behavior (SDSCA) of
curious users, active users, and nonusers.
EQ-5D, WHO-5, PAID-5, and
SDSCA
𝑛 (%)/mean ± SD/median (25–75
quartiles)
Nonusers
(𝑛 = 361) Missing
Curious users
(𝑛 = 184) Missing
Active users
(𝑛 = 88) Missing
Univariate
𝑝 value


























36 (12.6) 76 (21.1) 8 (5.3) 33 (17.9) 9 (10.8) 1 (1.1) 0.018
WHO-5 answers advise
screening depression 43 (15.5) 76 (21.1) 6 (4.0) 33 (17.9) 11 (13.3) 1 (1.1) 0.002
PAID-5 total score 2.8 ± 3.12.0 (0.0–4.5) 76 (21.1)
1.8 ± 2.4
1.0 (0.0–3.0) 32 (17.4)
2.2 ± 2.5
1.0 (0.0–4.0) 1 (1.1) 0.016
PAID-5 score indicates distress 15 (5.3) 76 (21.1) 4 (2.6) 32 (17.4) 2 (2.4) 1 (1.1) 0.183
SDSCA
General diet in number of days 5.4 ± 1.86.0 (5.0–7.0) 76 (21.1)
5.5 ± 1.9
6.0 (5.0–7.0) 32 (17.4)
5.8 ± 1.7
6.0 (5.5–7.0) 5 (5.7) 0.258
Specific diet in number of days 5.6 ± 1.15.7 (4.7–6.3) 73 (20.2)
5.7 ± 1.0
6.0 (5.0–6.7) 30 (16.3)
5.7 ± 1.0
6.0 (5.3–6.6) 4 (4.5) 0.160
Exercise in number of days 4.0 ± 2.04.0 (2.5–5.5) 72 (19.9)
4.1 ± 1.8
4.0 (2.9–5.6) 30 (16.3)
3.8 ± 1.8
3.8 (2.5–5.0) 4 (4.5) 0.612
Blood-glucose in number of
days
2.1 ± 2.2
1.0 (0.0–4.0) 74 (20.5)
2.1 ± 2.4
1.0 (0.0–4.0) 30 (16.3)
1.8 ± 1.8
1.0 (0.5–2.3) 4 (4.5) 0.241
Foot-care in number of days 1.9 ± 2.01.5 (0.0–3.5) 72 (19.9)
1.9 ± 2.0
1.0 (0.0–3.5) 30 (16.3)
1.8 ± 2.0
1.0 (0.0–3.5) 4 (4.5) 0.924
Medication in number of days 6.7 ± 1.07.0 (7.0–7.0) 73 (20.2)
7.0 ± 0.2
7.0 (7.0–7.0) 30 (16.3)
6.8 ± 0.8
7.0 (7.0–7.0) 4 (4.5) 0.020
Smoking 54 (25.1) 146 (40.4) 24 (21.8) 74 (40.2) 14 (24.6) 31 (35.2) 0.704
Appendices
A. Results of Users and Nonusers of
the Online Care Platform e-Vita
See Tables 4, 5, 6, 7, and 8.
B. Results of Curious Users,
Active Users, and Nonusers of
the Online Care Platform e-Vita
See Tables 9, 10, 11, 12, and 13.
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